DUBLIN – Shares in Pharnext SA gained 25 percent Tuesday after the company announced that its lead drug, PXT-3003, hit the primary endpoint of a phase III trial in type 1A Charcot-Marie-Tooth disease (CMT1A). Pharnext now plans to file for approval in the U.S. and Europe in the second half of 2019.